Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) announced that its subsidiary Shanghai Shangxiao Zhongxi Pharmaceutical Co., Ltd. has recently received a drug registration certificate from the Philippines Food and Drug Administration for its aripiprazole tablets, granting market approval for the product. Aripiprazole tablets are an antipsychotic medication primarily used for treating schizophrenia and manic episodes associated with bipolar disorder, and can also serve as an adjunctive treatment for depression.